Stockreport

How The Pulmonx (LUNG) Investment Story Is Shifting After Q4 And New Guidance [Yahoo! Finance]

Pulmonx Corporation  (LUNG) 
US:NASDAQ Investor Relations: investor.prolunginc.com/investor-relations
PDF Pulmonx is back in focus after analysts trimmed the price target from US$6 to US$5, while keeping a model fair value estimate of US$5.17 per share unchanged. This shift [Read more]